Physician profile
Lisa D Boyd
NPI 1306025218
$7,298.14
in general payments reported to CMS, 2019-2025
28 companies · $752 in 2025
The $752 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,689 · 2020: $1,033 · 2021: $765 · 2022: $379 · 2023: $815 · 2024: $864 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,030.73 | 2019-2024 | Uzedy, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $681.53 | 2019-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $591.04 | 2019-2023 | Trintellix |
| Abbvie INC. | $552.55 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $550.28 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $514.90 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $511.37 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $430.31 | 2019-2020 | |
| Corium, LLC | $311.73 | 2021-2023 | Azstarys |
| Tris Pharma INC | $266.01 | 2019-2023 | Quillivant, Dyanavel Xr, Quillichew Er |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $243.79 | 2023-2024 | Caplyta |
| Jazz Pharmaceuticals INC. | $234.86 | 2019-2021 | |
| Alkermes, INC. | $225.79 | 2022-2025 | Lybalvi |
| Axsome Therapeutics, INC. | $166.50 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $165.08 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $148.54 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $120.12 | 2025 | |
| Eisai INC. | $117.77 | 2020-2021 | |
| Bausch Health US, LLC | $106.78 | 2020-2025 | Aplenzin |
| Sunovion Pharmaceuticals INC. | $67.84 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $46.50 | 2019 | |
| Lundbeck LLC | $44.81 | 2019 | |
| Adlon Therapeutics L.P. | $43.49 | 2019-2020 | |
| Shire North American Group INC | $41.37 | 2019 | |
| Owp Pharmaceuticals, INC. | $23.78 | 2025 | Subvenite |
| Acadia Pharmaceuticals INC | $23.30 | 2025 | Nuplazid |
| Avanir Pharmaceuticals, INC. | $21.23 | 2019 | |
| Noven Therapeutics, LLC | $16.14 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.